MelaFind® is used during a skin exam or mole check to help Dr. Sax examine irregular moles
The primary goal of a skin exam is to help your dermatologist identify potentially harmful moles that could be skin cancer. Before MelaFind®, dermatologists used their eyes alone or with a hand-held magnifier to determine if a mole needed to be removed (i.e., biopsied). MelaFind® is designed for use on moles that are peculiar During a skin exam, dermatologists use the ABCDE-PRU’s of melanoma (see below) to evaluate moles. While almost all melanomas have one or more of the features outlined in the ABCDE-PRU rules, many irregular moles are not melanomas and are completely harmless. The hard part is determining which of these irregular moles should be biopsied. MelaFind can now be used to see more information beneath the surface of the mole about how irregular the mole is.
MelaFind & Melanoma Fact Sheet Do you have any moles on your body that look like these? If so, MelaFind may be right for you. Learn more about irregular moles and melanoma from this 2 page fact sheet.
MelaFind® Patient Brochure Provides you with information about MelaFind®, as well as facts about melanoma, and how you can monitor your own moles.
MelaFind® Patient FAQs Answers some of the top frequently asked questions (FAQs) about MelaFind® and melanoma.
The first CE Mark and FDA approved system that identifies over 95% of melanomas
Proven to be highly sensitive in detecting melanomaIn a very large pivotal study, MelaFind® correctly identified 98.3% of melanomas (172 out of 175). Most of these melanomas were at the most curable stage indicating that MelaFind® may help dermatologists detect more melanomas at the most readily treatable stages. In the same clinical study, patients with 45% of the melanomas biopsied did not have any major risk factors for melanoma such as previous history of skin cancer and history of sunburns.
Unfortunately, dermatologists don’t always catch melanoma with the naked eye or with the use of a dermoscope.
Studies show dermatologists may not elect to biopsy up to 30% of curable melanomas.
Fewer biopsies of benign irregular moles
In the study, MelaFind® correctly called more normal moles “Low disorganization” than dermatologists, which could mean fewer biopsies of moles that were benign.